Reuters - Shares of Celgene Corp (CELG.O) soared 13 percent on Thursday after it surprisingly announced that a clinical trial involving its multiple myeloma drug Revlimid showed clear benefit in newly diagnosed patients. A trial known as MM-015 showed a highly statistically significant improvement in progression-free survival for patients taking Revlimid as a first-line treatment for multiple myeloma, suggesting it could be approved for use in this setting earlier than expected.
